<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Immunology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31214171</article-id>
<article-id pub-id-type="pmc">6555258</article-id>
<article-id pub-id-type="doi">10.3389/fimmu.2019.01187</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hogan</surname>
<given-names>Kelly A.</given-names>
</name>
<uri xlink:href="http://loop.frontiersin.org/people/714321/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chini</surname>
<given-names>Claudia C. S.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chini</surname>
<given-names>Eduardo N.</given-names>
</name>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/645656/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff><institution>Signal Transduction and Molecular Nutrition Laboratory, Kogod Center on Aging, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine</institution>, <addr-line>Rochester, MN</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Silvia Deaglio, University of Turin, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Antje Garten, Leipzig University, Germany; Yasser Mohamed El-Sherbiny, Nottingham Trent University, United Kingdom</p>
</fn>
<corresp id="c001">*Correspondence: Eduardo N. Chini <email>chini.eduardo@mayo.edu</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Inflammation, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>31</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>1187</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>5</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Hogan, Chini and Chini.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Hogan, Chini and Chini</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>CD38 (Cluster of Differentiation 38) is a multifunctional ecto-enzyme that metabolizes NAD+ and mediates nicotinamide dinucleotide (NAD+) and extracellular nucleotide homeostasis as well as intracellular calcium. CD38 is also an emerging therapeutic target under conditions in which metabolism is altered including infection, aging, and tumorigenesis. We describe multiple enzymatic activities of CD38, which may explain the breadth of biological roles observed for this enzyme. Of greatest significance is the role of CD38 as an ecto-enzyme capable of modulating extracellular NAD+ precursor availability: 1 to bacteria unable to perform de novo synthesis of NAD+; and 2 in aged parenchyma impacted by the accumulation of immune cells during the process of ‘inflammaging’. We also discuss the paradoxical role of CD38 as a modulator of intracellular NAD+, particularly in tumor immunity. Finally, we provide a summary of therapeutic approaches to CD38 inhibition and ‘NAD+ boosting’ for treatment of metabolic dysfunction observed during aging and in tumor immunity. The present review summarizes the role of CD38 in nicotinamide nucleotide homeostasis with special emphasis on the role of CD38 as an immunomodulator and druggable target.</p>
</abstract>
<kwd-group>
<kwd>CD38</kwd>
<kwd>NADase</kwd>
<kwd>NAD+</kwd>
<kwd>aging</kwd>
<kwd>cancer</kwd>
<kwd>metabolism</kwd>
<kwd>senescence</kwd>
<kwd>macrophages</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">Mayo Foundation for Medical Education and Research<named-content content-type="fundref-id">10.13039/100007048</named-content></funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="6"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="111"></ref-count>
<page-count count="12"></page-count>
<word-count count="8227"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Historically, CD38 was considered a surface marker used to identify T cells (<xref ref-type="bibr" rid="B1">1</xref>). Our discovery that CD38 is the main nicotinamide dinucleotide (NAD<sup>+</sup>) catabolic enzyme has shed light on the relevance of this enzyme in organismal NAD<sup>+</sup> metabolism and has implications for several pathophysiological conditions including infection, aging, tumorigenesis (<xref ref-type="bibr" rid="B2">2</xref>–<xref ref-type="bibr" rid="B6">6</xref>). Furthermore, a more sophisticated understanding of the structure and function of CD38 has led to identification of therapeutic targets and potential treatments for conditions associated with metabolic dysfunction in infection, aging, and cancer (<xref ref-type="bibr" rid="B7">7</xref>–<xref ref-type="bibr" rid="B10">10</xref>). The role of CD38 in other organ systems, such as the central nervous system, has also been described. These studies focus on oxytocin signaling and social behavior in mice (<xref ref-type="bibr" rid="B11">11</xref>–<xref ref-type="bibr" rid="B14">14</xref>) and have been reviewed previously (<xref ref-type="bibr" rid="B15">15</xref>). Thus, the present review will provide an overview of CD38 enzymology; focus on recent advances in CD38-mediated age-related metabolic dysfunction and tumor immunometabolism; and summarize pharmacological approaches to CD38 inhibition.</p>
<sec>
<title>The Different Enzymatic Activities of CD38 Provide Diversity in Its Biological Roles</title>
<p>The surface marker and multifunctional enzyme CD38 appears to provide a link between inflammation and age- and disease-related decline in tissue homeostasis and, therefore, represents a critical target for therapeutic intervention. CD38 is expressed predominately on immune cells in response to stimulation by cytokines, endotoxins, and interferon (<xref ref-type="bibr" rid="B16">16</xref>–<xref ref-type="bibr" rid="B18">18</xref>). Expression of the enzyme is regulated by a promoter region containing binding sites for NF-kB, RXR, LXR, and STAT suggesting that it plays a key role in the inflammatory response (<xref ref-type="bibr" rid="B18">18</xref>). CD38 expression causes a substantial decline in cellular NAD<sup>+</sup> levels, thus altering the availability of substrates for enzymes regulating cellular homeostasis. Thus, infiltration of CD38-expressing immune cells during infection, aging, or tumorigenesis has the potential to: alter NAD<sup>+</sup> homeostasis in parenchymal tissues or the tumor microenvironment; disrupt normal metabolic processes; and undermine tissue integrity.</p>
<p>The identification of CD38 as a key modulator of NAD<sup>+</sup> metabolism in the context of cell signaling, aging, and tumor biology suggests that the enzyme is a target of promising therapeutic potential. CD38 is paradoxical in its mode of action, diverse in its locale, and functionally pleotropic, and thus presents numerous drug design challenges and opportunities. CD38 is positioned in the cellular membrane with its catalytic site facing toward the extracellular environment in a type II orientation (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref ref-type="bibr" rid="B19">19</xref>–<xref ref-type="bibr" rid="B21">21</xref>). Functionally, over 90% of CD38 acts as an ecto-NADase that catabolizes β-NAD<sup>+</sup> (<xref ref-type="bibr" rid="B20">20</xref>). Given the abundance of intracellular NAD<sup>+</sup>, the presence of an extracellular catalytic site presents a topological paradox (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B21">21</xref>). Our laboratory and others demonstrate that, in addition to NAD<sup>+</sup>, CD38 metabolizes extracellular NAD<sup>+</sup> precursors (NMN and NR) prior to their transport into the cell for NAD<sup>+</sup> biosynthesis (<xref ref-type="bibr" rid="B5">5</xref>). We have shown that the ecto-NMNase activity of CD38 plays a critical role in the regulation of nicotinamide nucleotides during the aging process (<xref ref-type="bibr" rid="B5">5</xref>). These findings suggest that the role of type II membrane-bound CD38 is to maintain NAD<sup>+</sup> homeostasis by regulating precursors of NAD<sup>+</sup> synthesis in the extracellular environment, thus calling into question the veracity of a topological paradox. Another outstanding question in the field is the role of intracellular forms of CD38. As discussed above, a small percent of CD38 can have its catalytic site facing the intracellular environment. Examples include the transmembrane Type III CD38 that has its c-terminal facing intracellularly; CD38 present in the nucleus and mitochondrial membrane; and a likely soluble form of CD38 present in the cytoplasm (<xref ref-type="fig" rid="F1">Figure 1</xref>). In these configurations CD38 would have access to the intracellular pools of NAD<sup>+</sup> and, without significant regulation, could lead to a severe decline in intracellular NAD<sup>+</sup> and result in metabolic collapse (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Role of CD38 in NAD<sup>+</sup> metabolism. CD38 is predominantly expressed on immune cells and metabolizes nicotinamide nucleotides (NAD<sup>+</sup> and NMN) to ADPR and cADPR, which results in the mobilization of calcium. Although intracellular CD38 is present in the cytoplasm and in the membranes of organelles, a vast majority of CD38 activity is extracellular, which results in degradation of NAD<sup>+</sup> precursors (e. g., NMN) necessary for NAD<sup>+</sup> synthesis. Extracellular activity of CD38 has wide ranging implications for NAD<sup>+</sup> homeostasis in the context of infection, metabolic dysfunction, aging, and tumor biology.</p>
</caption>
<graphic xlink:href="fimmu-10-01187-g0001"></graphic>
</fig>
<p>The role of CD38 as a second messenger enzyme for the synthesis of cADPR is also proposed (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref ref-type="bibr" rid="B21">21</xref>–<xref ref-type="bibr" rid="B24">24</xref>). Interestingly, CD38 is a very inefficient cyclase and must degrade nearly 100 molecules of NAD<sup>+</sup> to generate one molecule of cADPR (<xref ref-type="fig" rid="F2">Figure 2</xref>) (<xref ref-type="bibr" rid="B7">7</xref>). It is possible that the generation of cADPR could be part of a byproduct of the NAD<sup>+</sup> glycohydrolase activity of CD38. Furthermore, the structurally unrelated enzyme SARM1 has NAD<sup>+</sup> glycohydrolase activity and generates a very small fraction of cADPR during its catalysis (<xref ref-type="bibr" rid="B25">25</xref>). This may indicate that the NADase activity of SARM also generates cADPR as a byproduct. Thus, the widely accepted notion that CD38 is mainly an ADP-ribosyl cyclase is misleading based on the fact that its primary role is to degrade nicotinamide nucleotides such as NAD<sup>+</sup> and NMN. Therefore, we propose that the main enzymatic activity of CD38 is not an ADP-ribosyl cyclase, but rather an NAD<sup>+</sup> glycohydrolase (<xref ref-type="fig" rid="F2">Figure 2</xref>) and that both CD38 and SARM1 should be characterize based on their main enzymatic activity, namely the NAD/NMNase. In spite of these enzyme classifications, it is clear that cADPR is a second messenger that regulates intracellular calcium homeostasis in several cells (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>CD38 is primarily an NAD<sup>+</sup> glycohydrolase, which degrades nicotinamide nucleotides. In addition to the NAD<sup>+</sup> glycohydrolase activity, CD38 exhibits inefficient ADP-ribosyl cyclase activity and mediates a base-exchange of vitamin B3 bases in the presence of excess nicotinamide analogs.</p>
</caption>
<graphic xlink:href="fimmu-10-01187-g0002"></graphic>
</fig>
<p>Another role for CD38 is the regulation of extracellular adenosine, which requires consumption of NAD<sup>+</sup>. The synthesis of adenosine from NAD<sup>+</sup> is a complementary mechanism similar to the CD39/CD73-mediated catabolism of ATP to adenosine (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>). Adenosine is important in immune modulation because it has been implicated in immune suppression through purinergic receptor binding (<xref ref-type="fig" rid="F1">Figure 1</xref>) and in the immunomodulation of multiple myeloma (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>) and lung cancer (<xref ref-type="bibr" rid="B30">30</xref>). Thus, involvement of CD38 in the regulation of NAD<sup>+</sup> and adenosine homeostasis has led to some speculation that CD38 may function as an immune check point molecule (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>).</p>
<p>In addition to the NAD<sup>+</sup> glycohydrolase and ecto-NMNase activity of CD38, the enzyme catalyzes the base-exchange reaction that leads to an exchange of vitamin B3 bases on a molecule (<xref ref-type="fig" rid="F2">Figure 2</xref>). This reaction is optimal in the presence of excess nicotinamide analogs and at low pH; however, this reaction can also be catalyzed at physiological pH (<xref ref-type="bibr" rid="B33">33</xref>–<xref ref-type="bibr" rid="B35">35</xref>). One of the potential molecules that can be generated by this reaction is the nicotinic acid derivative of NADP (NAADP) (<xref ref-type="fig" rid="F2">Figure 2</xref>) (<xref ref-type="bibr" rid="B36">36</xref>). Whether this reaction occurs in cells naturally expressing CD38 or <italic>in vivo</italic> is unknown; however, the synthesis of NAADP by CD38 by a base-exchange reaction in lysosomes would have implications for intracellular calcium homeostasis. Interestingly, NAADP levels in tissues and cells appear to be independent of the CD38 expression (<xref ref-type="bibr" rid="B33">33</xref>–<xref ref-type="bibr" rid="B36">36</xref>), indicating that CD38 independent NAADP synthesis exists in mammalian tissues. One of the potential candidates for the synthesis of NAADP is the newly discovered NADase SARM1.</p>
<p>In any case, it appears that the base-exchange reaction operates <italic>in vivo</italic> when excess nicotinamide analogs are available to tissues (<xref ref-type="fig" rid="F2">Figure 2</xref>) (<xref ref-type="bibr" rid="B37">37</xref>). For example, we have demonstrated that CD38 is responsible for the synthesis of isoniazid derivatives of NAD<sup>+</sup> and NADP<sup>+</sup> in animals given toxic doses of this anti-tuberculosis medication (<xref ref-type="bibr" rid="B37">37</xref>). Isoniazid is a nicotinamide derivative that can serve as a substrate for the CD38-mediated base-exchange reaction (<xref ref-type="bibr" rid="B37">37</xref>). Thus, it is possible that the CD38 base-exchange reaction is partially responsible for the <italic>in vivo</italic> toxicity of isoniazid through the formation of toxic NAD<sup>+</sup> intermediates during drug metabolism. It is important to highlight that, in addition to its enzymatic activity, CD38 could have enzymatic-independent roles in cell migration and homing through interaction with adhesion molecules such as CD31 (<xref ref-type="bibr" rid="B38">38</xref>).</p>
</sec>
<sec>
<title>CD38 Has a Role in the Immune Response to Microbes</title>
<p>An important and still outstanding question is why inflammatory cells express CD38. The inability of bacteria such as <italic>H. influenza</italic> to recycle or perform <italic>de novo</italic> synthesis of NAD<sup>+</sup> may provide insight into the role of CD38 in response to infection (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>). These pathogens, including <italic>H. aegyptius, H. influenzae, H. haemolyticus, H. parainfluenzae, and H. parahaemolyticus</italic>, are responsible for a spectrum of infections, and lack the ability to synthesize NAD<sup>+</sup> and rely instead on uptake of NAD<sup>+</sup> and NAD<sup>+</sup> precursor molecules (e. g., NMN, NR) to support metabolism and growth (<xref ref-type="bibr" rid="B40">40</xref>). In fact, NAD<sup>+</sup> and its precursors are necessary for the growth of bacteria and have to be included in culture media as the V-factor (<xref ref-type="fig" rid="F3">Figure 3</xref>) (<xref ref-type="bibr" rid="B39">39</xref>). Interestingly, these bacteria express nucleotide transporters to facilitate intracellular incorporation (<xref ref-type="bibr" rid="B40">40</xref>). The presence of CD38 ecto-nicotinamide nucleotidase in activated immune cells may reduce the availability of NAD<sup>+</sup> to bacteria and other pathogens and could limit the development or progression of infections. This process may occur not only extracellularly but also in the intracellular space. Indeed, we have demonstrated previously that CD38<sup>+</sup> macrophages limit the growth of some obligatory intracellular bacteria (<xref ref-type="bibr" rid="B18">18</xref>). We propose that CD38, as either an ecto-enzyme or as an intracellular enzyme, promotes metabolic collapse in pathogens by degrading NAD<sup>+</sup> and its precursors.</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>CD38 may alter the availability of NAD<sup>+</sup> precursors. CD38+ cells may limit the growth of pathogens such as <italic>H. aegyptius, H. influenzae, H. haemolyticus, H. parainfluenzae</italic>, and <italic>H. parahaemolyticus</italic> by degrading extracellular NAD<sup>+</sup> precursors required for NAD<sup>+</sup> synthesis in bacteria. In the absence of NAD and its precursors (V factor), pathogens undergo metabolic collapse.</p>
</caption>
<graphic xlink:href="fimmu-10-01187-g0003"></graphic>
</fig>
<p>In addition to macrophages, which express CD38 in M1 polarization (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>), others have reported a role for CD38 in neutrophil- and T cell-mediated immune response (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B44">44</xref>). Neutrophils lacking CD38 demonstrate altered mobilization from the bone marrow and migration to sites of infection (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>). CD38<sup>+</sup> T cells play a myriad of roles in acute and chronic infections including the ability to be cytotoxic (<xref ref-type="bibr" rid="B47">47</xref>) as well as inhibit an immune response (<xref ref-type="bibr" rid="B48">48</xref>). What remains unknown is whether some effects are mediated by the enzymatic or non-enzymatic roles of CD38. Taken together, expression of CD38 on immune cells appears to play a role in the immune system, particularly in the context of infection.</p>
</sec>
<sec>
<title>CD38 in Aging and Age-Related Metabolic Dysfunctions</title>
<p>Unlike an immune response to infection, inflammaging is a “sterile” inflammatory response which is cytokine-mediated and prompted by damage to DNA and proteins as well as a diminished capacity for cell repair in the aging organism (<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>). In age-related decline, there is a reduction of NAD<sup>+</sup>, a master regulator of metabolism, which when reduced is a cofactor in electron transport during oxidation-reduction reactions. Furthermore, NAD<sup>+</sup> is a critical molecule in cell signaling, intracellular calcium regulation, and chromatin remodeling (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B51">51</xref>–<xref ref-type="bibr" rid="B53">53</xref>). NAD<sup>+</sup> has emerged as a molecule that provides a link between signaling and metabolism. Decline of NAD<sup>+</sup> levels is very likely a key player in the pathogenesis of several diseases including age-related conditions (<xref ref-type="fig" rid="F4">Figure 4</xref>) (<xref ref-type="bibr" rid="B4">4</xref>–<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B54">54</xref>–<xref ref-type="bibr" rid="B61">61</xref>).</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>NAD<sup>+</sup> decline has been implicated in several diseases and age-related conditions. NAD<sup>+</sup> decline has been implicated in the biology of aging and in several conditions in rodents. In humans, NAD decline has been implicated in pellagra, acute kidney injury, and the fetal malformation syndrome (VACTERL association), which affects many organ systems during development.</p>
</caption>
<graphic xlink:href="fimmu-10-01187-g0004"></graphic>
</fig>
<p>Until recently, age-related NAD<sup>+</sup> decline was thought to be a consequence of activation of NAD<sup>+</sup>-consuming DNA-repair enzymes such as Poly-ADP-ribosylating enzymes (PARPs) or decrease in NAD<sup>+</sup> synthesis (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B62">62</xref>). Unlike CD38, PARPs are found exclusively in the intracellular compartment, more specifically in the nuclei (<xref ref-type="bibr" rid="B9">9</xref>). PARPs are activated by DNA damage and catalyze the NAD-dependent polymerization of a chain of polymeric adenosine diphosphate ribose (poly (ADP-ribose) or PAR, which signals repair of DNA. PARPs lead to intranuclear and intracellular NAD<sup>+</sup> consumption and NAD<sup>+</sup> collapse (<xref ref-type="bibr" rid="B9">9</xref>). Additionally, levels of the rate-limiting NAD<sup>+</sup> synthesis enzyme NAMPT decrease in some aging tissues (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>) indicating a diminished capacity to generate intracellular NAD<sup>+</sup> by salvage pathway synthesis and reliance on import of extracellular NAD<sup>+</sup> precursors NMN and NR.</p>
<p>We have shown that genetic ablation of CD38 protects against age-related NAD<sup>+</sup> decline and mitochondrial dysfunction. Furthermore, levels and activity of CD38 increase during aging (<xref ref-type="bibr" rid="B5">5</xref>). Recently, we proposed that NAD<sup>+</sup> decline during aging in cells/tissues is related to exposure to factors related to the senescence associated secretory phenotype (SASP) which may increase CD38 expression in these cells/tissues. In fact, we demonstrated that SASP conditioned media from senescence cells can induce CD38 expression in both macrophages and endothelial cells (<xref ref-type="bibr" rid="B65">65</xref>). Thus, it is possible that the senescent phenotype drives the accumulation of CD38<sup>+</sup> inflammatory cells, which modulate the availability of NAD<sup>+</sup> precursors, and plays a crucial role in the metabolism of nicotinamide nucleotide (<xref ref-type="fig" rid="F5">Figure 5</xref>) (<xref ref-type="bibr" rid="B65">65</xref>).</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>CD38 expression in macrophages mediate “inflammaging.” The senescence associated senescent phenotype (SASP) appears to drive the expression of CD38 in macrophages. During inflammaging, CD38+ macrophages accumulate in aging tissues and potentiate the decline of precursors necessary for NAD<sup>+</sup> synthesis.</p>
</caption>
<graphic xlink:href="fimmu-10-01187-g0005"></graphic>
</fig>
</sec>
<sec>
<title>CD38 in Immune Metabolism and Tumor Biology</title>
<p>Age-related diseases such as cancer provide an interesting context for considering ways in which immune cells are modulated by the tumor microenvironment as well as targeted by immune-based therapies. Emerging data demonstrate that CD38 knockout mice under high metabolic pressure, such as high fat diets, are protected against the development of cancers and have increased longevity (<xref ref-type="bibr" rid="B62">62</xref>). Interestingly, the role of CD38 in the tumor cell provides somewhat conflicting data. For example, pancreatic and prostate cancer, which exhibit low CD38 expression and increased cellular NAD<sup>+</sup> levels, exhibit increased tumor cell survival (<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B67">67</xref>). Increased CD38 activity in both adenocarcinomas, results in decreased intracellular NAD<sup>+</sup>, diminished cell growth, and increased apoptosis and cellular senescence (<xref ref-type="bibr" rid="B66">66</xref>–<xref ref-type="bibr" rid="B68">68</xref>).</p>
<p>On the other hand, metabolic reprogramming of NAD<sup>+</sup> regulation via inhibition of CD38 has been proposed as a strategy for improving efficacy of immune-based therapies. CD38, in particular, appears to play a significant role in the regulation of metabolism and immunomodulation of the tumor microenvironment (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B69">69</xref>–<xref ref-type="bibr" rid="B76">76</xref>).</p>
<p>CD38 has emerged recently as a component of mitochondrial transfer/trafficking between cells (<xref ref-type="bibr" rid="B77">77</xref>, <xref ref-type="bibr" rid="B78">78</xref>). For many years, it has been demonstrated that cells can transfer their mitochondria to other cells, particularly cancer cells (<xref ref-type="bibr" rid="B79">79</xref>–<xref ref-type="bibr" rid="B84">84</xref>). However, components of this intriguing biological process have not been identified. In particular, it has been shown that multiple myeloma cells may take or receive mitochondria from non-malignant bone marrow stromal cells. This transfer occurs via a CD38-dependnet tumor-derived tunneling nanotubes (<xref ref-type="bibr" rid="B78">78</xref>). The precise enzymatic, structural, and signaling roles for CD38 in this process have not been described.</p>
</sec>
<sec>
<title>CD38 Regulates Anti-Tumor T Cell Exhaustion</title>
<p>Recently, metabolic reprogramming of the CD38-NAD<sup>+</sup> axis in CD4<sup>+</sup> T cells has shown to be a promising approach to adoptive T cell (ACT) therapy (<xref ref-type="bibr" rid="B75">75</xref>). ACT therapy involves the <italic>ex vivo</italic> alteration, expansion, and transfer of tumor epitope reactive autologous T cells to a tumor bearing host. What results is a population of T cells with enhanced anti-tumor potential. The dependence of CD4<sup>+</sup> T cells on an array of metabolites deems this population a particularly robust target for metabolic reprogramming (<xref ref-type="bibr" rid="B85">85</xref>). Chatterjee et al. report a strategy in which Th1 and Th17 cells are merged into hybrid Th1/17 cells, which rely on glutamine-driven oxidative phosphorylation (glutaminolysis) (<xref ref-type="bibr" rid="B75">75</xref>). This shift toward glutaminolysis confers greater survival of Th1/17 cells, elevated secretion of IFN-γ and IL-17 production, and enhanced anti-tumor activity (<xref ref-type="fig" rid="F6">Figure 6</xref>). Curiously, Th1/17 cells demonstrate robust activity of the transcription factor Foxo1, which controls T cell memory and is responsible for the anti-tumor phenotype of the Th1/17 hybrid cell type. Induction of Foxo1 occurs by deacetylation by NAD<sup>+</sup>-dependent Sirt1 and is essential to the immune response of T cells. Chatterjee et al. demonstrate that, in addition to increased Foxo1 activity, Th1/17 exhibit higher levels of NAD<sup>+</sup> and reduced CD38 expression (<xref ref-type="bibr" rid="B75">75</xref>). The significance of this finding is that increased NAD<sup>+</sup> levels improve the anti-tumor response of Th1/17 by providing a substrate for Sirt1. Chatterjee observed a similar phenotype in CD38-deficient natural killer (NK) cells, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs) (<xref ref-type="bibr" rid="B75">75</xref>). What remains unknown, however, is how glutaminolysis controls production of NAD<sup>+</sup> and whether CD38 inhibition is a function of glutamine catabolism.</p>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption>
<p>Role of CD38 in immunometabolism and tumor biology. Using a strategy that merges Th1 and Th17 cells into a hybrid Th1/Th17 cell, the CD38-NAD<sup>+</sup> axis undergoes metabolic reprogramming. Reprogramming results in a shift toward glutamine-driven oxidative phosphorylation, which improves T cell survival, immune cell recruitment to the tumor, and T cell memory. Th1/Th17 hybrid cells also demonstrate reduced expression of CD38 and higher levels of NAD<sup>+</sup>, which serves as a substrate for NAD<sup>+</sup> -dependent Sirt1 deacetylase activity that is essential to the T cell response.</p>
</caption>
<graphic xlink:href="fimmu-10-01187-g0006"></graphic>
</fig>
</sec>
<sec>
<title>CD38: A New Immune Check Point?</title>
<p>Programmed death-ligand 1 (PD-L1, B7-H1, or CD274) is present on the surface of dendritic cells or macrophages, but is also frequently over-expressed in tumor cells. Tumor cells co-opt the PD-L1 in order to evade T cell surveillance (<xref ref-type="bibr" rid="B86">86</xref>). CD8<sup>+</sup> cytotoxic T cells treated with checkpoint inhibitors such as PD-1/PD-L1 blocking antibodies demonstrate temporal upregulation of CD38 (<xref ref-type="bibr" rid="B87">87</xref>). Increased CD38 activity, in turn, results in CD8<sup>+</sup> T cell suppression (<xref ref-type="bibr" rid="B73">73</xref>). This phenomenon may in part explain the high drug resistance rates observed in patients treated with PD-1/PD-L1 blockers (<xref ref-type="bibr" rid="B88">88</xref>). The mechanism by which CD38 mediated PD-1/PD-L1 blockade resistance likely includes perturbation of adenosine receptor signaling in tumor microenvironment leading to immune modulation (<xref ref-type="bibr" rid="B87">87</xref>). CD38 expression in tumors is a biomarker of poor response to checkpoint inhibitor therapy (<xref ref-type="bibr" rid="B88">88</xref>). One possible approach to ameliorate resistance to PD-1/PD-L1blockade is co-inhibition of CD38, which may re-establish the immune response of T cells to the tumor. Taken together, CD38 inhibition is emerging as a potential therapeutic strategy for shaping the immunometabolome of host T cells in order to enhance immune response to tumor cells.</p>
</sec>
<sec>
<title>CD38 in Fetomaternal Tolerance</title>
<p>Successful pregnancy requires the establishment of maternal immune tolerance to the fetus (<xref ref-type="bibr" rid="B89">89</xref>). For the uterine environment to be receptive to pregnancy, there must be activation, differentiation, and expansion of toleragenic dendritic cells (tDCs) and CD4<sup>+</sup>CD25<sup>+</sup> Treg cells (<xref ref-type="bibr" rid="B90">90</xref>, <xref ref-type="bibr" rid="B91">91</xref>) Evidence from a CBAxDBA/2 mouse model of pregnancy failure suggests that components of seminal fluid prime the immunological landscape of the uterine environment for implantation (<xref ref-type="bibr" rid="B92">92</xref>). Several years ago our group demonstrated that human seminal fluid contains high amounts of a soluble 49 kDa CD38 enzyme (<xref ref-type="bibr" rid="B93">93</xref>). Interestingly, the glycohydrolase activity of CD38 in the seminal fluid is significantly inhibited by the high zinc content of the seminal fluid (<xref ref-type="bibr" rid="B93">93</xref>). These data raise the possibility that seminal fluid CD38 could control the metabolic fate of NAD<sup>+</sup> and adenosine and regulate sperm and fetomaternal tolerance. A study by Kim and colleagues demonstrated that in matings between CD38<sup>−/−</sup> male mice and wild type females, embryo reabsorption rates are higher, and fewer total and viable implantations sites are observed suggesting a role for CD38 in establishing pregnancy (<xref ref-type="bibr" rid="B94">94</xref>). Indeed, tDCs and Foxp3<sup>+</sup> Tregs were induced by soluble seminal CD38 through a CD31- independent pathway (<xref ref-type="bibr" rid="B94">94</xref>). These data indicate that CD38 may play a similar role in fetomaternal tolerance in humans and further highlight the physiological role of CD38 in immunomodulation. What remains poorly understood, however, is the specific mechanism of CD38 enzymatic activity at the fetomaternal tolerance. For example, it is not known if CD38-mediated regulation of NAD<sup>+</sup> metabolism or the accumulation of adenosine is involved in establishing tolerance between mother and fetus.</p>
</sec>
</sec>
<sec id="s2">
<title>Pharmacological Approaches to Targeting/Modulating CD38 Ecto- and Endo Enzymatic Activity</title>
<p>Based on the multi-faceted roles of CD38, there are extensive opportunities for design of molecules capable of inhibiting this enzyme. Below we summarize those molecules and discuss their potential as immunomodulatory therapeutics.</p>
<sec>
<title>Anti-CD38 Antibodies</title>
<p>Anti-CD38 monoclonal antibodies are shown to be highly efficacious in the treatment of multiple myeloma (MM) and pre-clinical studies highlight the potential use in other tumors such as CLL, lung cancer, prostate cancer and melanoma (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B72">72</xref>–<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B95">95</xref>–<xref ref-type="bibr" rid="B99">99</xref>) and in a preclinical model of melanoma (<xref ref-type="bibr" rid="B87">87</xref>). Currently, there are four monoclonal antibodies in clinical trials for the treatment of CD38<sup>+</sup> malignancies (<xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B95">95</xref>, <xref ref-type="bibr" rid="B96">96</xref>). These include Daratumumab (Janssen Biotech) (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B72">72</xref>, <xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B95">95</xref>–<xref ref-type="bibr" rid="B97">97</xref>), Isatuximab (Sanofi-Aventis) (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B98">98</xref>), MOR202 (Morphosys) (<xref ref-type="bibr" rid="B76">76</xref>), and TAK079 (Takeda) (<xref ref-type="bibr" rid="B100">100</xref>) (<xref ref-type="table" rid="T1">Table 1</xref>), which produce antibody-dependent cell-mediated toxicity (ADCC) and have comparable binding affinities and similar safety profiles. These antibody-based therapies, however, differ in their ability to induce direct apoptosis, mount complement-mediated cytotoxicity (CDC), inhibit CD38 directly, and induce antibody-dependent cell-mediated phagocytosis (ADCP) (<xref ref-type="table" rid="T1">Table 1</xref>) (<xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B96">96</xref>). The prevailing mechanism of action of anti-CD38 antibodies currently under investigation is hypothesized to be ADCC; however the therapeutic benefit may also involve inhibition of CD38 NADase activity and subsequent NAD<sup>+</sup> boosting. Recently, Chatterjee et al. raised the possibility that T cell function in the tumor microenvironment can be enhanced by inhibition of CD38 and increased availability of NAD<sup>+</sup> (<xref ref-type="bibr" rid="B75">75</xref>). This finding supports the tandem use of anti-CD38 antibodies and PD-1/PD-L1 checkpoint blockers to enhance the immune response to cancer, thereby providing a two-pronged approach to immunomodulation of the tumor microenvironment.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Therapeutic approaches to CD38 inhibition and immunomodulation.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Compound name</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Mechanism of action</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">NAD analogs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Covalent inhibitors</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ara-F-NAD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Competitive inhibition of NADase activity</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Ara-F-NFM</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Ara-F-NMN phosphoester/C48</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-covalent inhibitors</td>
<td align="left" colspan="1" rowspan="1" valign="top">Carba-NAD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Competitive inhibition of NADase activity</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Pseudo-Carba-NAD</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Apigenin</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Flavonoids</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Luteolinidin</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Kuromanin</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Rhein/K-Rhein</td>
<td align="left" colspan="1" rowspan="1" valign="top">Uncompetitive inhibition of NADase activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">4-amino- quinolines</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">78c</td>
<td align="left" colspan="1" rowspan="1" valign="top">Uncompetitive inhibition of NADase activity</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">1ah</td>
<td align="left" colspan="1" rowspan="1" valign="top">Competitive inhibition of NADase activity</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">1ai</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Antibodies (IgG mAB)</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Isatuximab</td>
<td align="left" colspan="1" rowspan="1" valign="top">Allosteric inhibition of NADase activity/Cytotoxic effect/clearance of CD38+ cells</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Daratumumab</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cytotoxic effect/clearance of CD38+ cells</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TAK-079</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">MOR-202</td>
<td colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TN1">
<p><italic>NAD<sup>+</sup> analogs, flavonoids, small molecule inhibitors (4-amino-quinolines), and antibodies have been shown to have therapeutic potential as immunomodulators in conditions of aging and tumor immunity</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec>
<title>Small Molecule CD38 Inhibitors and Derivatives of 4-Amino-Quinoline</title>
<p>There are over 200 compounds capable of inhibiting CD38 (<xref ref-type="table" rid="T1">Table 1</xref>). These compounds are classified as NAD analogs (<xref ref-type="bibr" rid="B101">101</xref>), flavonoids (<xref ref-type="bibr" rid="B102">102</xref>), and heterocyclic compounds (<xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B104">104</xref>) and can form either covalent or non-covalent bonds to amino acids located in the active site of CD38 (<xref ref-type="bibr" rid="B105">105</xref>). Elucidation of CD38 catalysis and active site crystallography has resulted in design of high affinity CD38 small molecule inhibitors (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B106">106</xref>). Small molecule derivatives of 4-amino-quinoline, in particular, are non-covalent and demonstrate an IC50 values in the nanomolar range (<xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B104">104</xref>) and include three lead compounds: 78c (IC50 7.3 nM), 1ai (IC50 46 nM), and Iah (IC50 115 nM). Mutagenesis studies implicate binding site residues that are important for NADase activity (<xref ref-type="bibr" rid="B105">105</xref>). Changes to these residues result in loss of glycohydrolase activity and increased cyclase activity. Small molecule blockade of CD38, therefore, compromises interactions between endogenous substrates (NAD<sup>+</sup>, NMN) and the active site. CD38 small molecule inhibitors show promise as NAD<sup>+</sup> boosting drugs in pre-clinical studies (<xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B106">106</xref>) and are likely to be important tools for understanding disease-specific roles for the multi-functional enzyme.</p>
</sec>
<sec>
<title>Flavonoids</title>
<p>Several naturally occurring compounds are reported to inhibit the catalytic activity of CD38 including flavonoid compounds apigenin, quercetin, and leteolinidin (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B102">102</xref>, <xref ref-type="bibr" rid="B107">107</xref>) (<xref ref-type="table" rid="T1">Table 1</xref>). Most flavonoids, with the exception of 4,5-dihydroxyanthrquinone-2-carboxylic acid (RHein), are competitive antagonists of CD38, which likely lead to an increase in cellular NAD<sup>+</sup> levels and activation of NAD-dependent enzymes such as SIRTUINs (<xref ref-type="bibr" rid="B8">8</xref>). Flavonoid CD38 inhibitors demonstrate a lack of toxicity in humans (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B102">102</xref>) and beneficial effects in animal models of obesity, heart ischemia, kidney injury, viral infection, and cancer (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B71">71</xref>, <xref ref-type="bibr" rid="B102">102</xref>, <xref ref-type="bibr" rid="B107">107</xref>, <xref ref-type="bibr" rid="B108">108</xref>). However, these compounds lack specificity and demonstrate off-target effects and a poor oral pharmacokinetic profile (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B102">102</xref>).</p>
</sec>
<sec>
<title>NAD<sup>+</sup> Analog Inhibitors</title>
<p>Based on the mechanisms of CD38 catalysis and crystal structure, NAD<sup>+</sup> analog inhibitors were developed by modifying nicotinamide ribose group within NAD<sup>+</sup> and NMN (<xref ref-type="bibr" rid="B101">101</xref>, <xref ref-type="bibr" rid="B109">109</xref>–<xref ref-type="bibr" rid="B111">111</xref>). These inhibitors include the low affinity, non-covalent inhibitor carba-NAD and ara-NAD (<xref ref-type="table" rid="T1">Table 1</xref>). Although these drugs may have potential as immunomodulators capable of increasing tumor suppressive effects (<xref ref-type="bibr" rid="B75">75</xref>), their utility may be limited by their inhibitory effects on NAD<sup>+</sup> consuming enzymes.</p>
</sec>
</sec>
<sec id="s3">
<title>Concluding Remarks</title>
<p>CD38 has emerged as a major NAD<sup>+</sup> consuming enzyme and as a regulator of NAD<sup>+</sup> homeostasis in several conditions. The primary role of CD38 in immunity has not been completely understood. However, it is possible that CD38 may have a key role in the immune response to bacterial infections. It has also been described that the CD38-NAD<sup>+</sup> axis controls metabolic reprogramming of T cells in the tumor microenvironment and contributes to drug resistance plaguing PD-1/PD-L1checkpoint inhibitors. As a central regulator of metabolism, maintenance of NAD<sup>+</sup> homeostasis is taking center stage as a modifier of health and disease. These findings highlight the potential drugability of CD38 as a target in metabolic dysfunction typically observed in the contexts of aging and tumor immunity. In addition, CD38 cytotoxic antibodies has been used to treat CD38 positive tumors such as multiple myeloma and potentially CLL. Thus, CD38 has both physiological and pathological roles as well as great potential as a therapeutic target in various human diseases.</p>
</sec>
<sec id="s4">
<title>Author Contributions</title>
<p>All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.</p>
</sec>
<sec>
<title>Conflict of Interest Statement</title>
<p>EC has a patent on CD38 inhibitors and is a consultant for Teneobio. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> The work in EC laboratory is supported in part by grants from the Ted Nash Long Life Foundation, the Glenn Foundation for Medical Research via the Paul F. Glenn Laboratories for Senescence at the Mayo Clinic, National Institutes of Health (NIH) grants from the National Institute of Aging (NIA, grants AG-26094, AG-58812), and the National Cancer Institute (NCI) via the Mayo Clinic pancreatic cancer SPORE program (CA 102701-14P2).</p>
<p>Funding from Calico Life Sciences. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golden-Mason</surname><given-names>L</given-names></name><name><surname>Curry</surname><given-names>MP</given-names></name><name><surname>Nolan</surname><given-names>N</given-names></name><name><surname>Traynor</surname><given-names>O</given-names></name><name><surname>McEntee</surname><given-names>G</given-names></name><name><surname>Kelly</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver</article-title>. <source/>Hepatology. (<year>2000</year>) <volume>31</volume>:<fpage>1251</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1053/jhep.2000.7713</pub-id><pub-id pub-id-type="pmid">10827150</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksoy</surname><given-names>P</given-names></name><name><surname>Escande</surname><given-names>C</given-names></name><name><surname>White</surname><given-names>TA</given-names></name><name><surname>Thompson</surname><given-names>M</given-names></name><name><surname>Soares</surname><given-names>S</given-names></name><name><surname>Benech</surname><given-names>JC</given-names></name><etal></etal></person-group>. <article-title>Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38</article-title>. <source/>Biochem Biophys Res Commun. (<year>2006</year>) <volume>349</volume>:<fpage>353</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2006.08.066</pub-id><pub-id pub-id-type="pmid">16935261</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksoy</surname><given-names>P</given-names></name><name><surname>White</surname><given-names>TA</given-names></name><name><surname>Thompson</surname><given-names>M</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group>. <article-title>Regulation of intracellular levels of NAD: a novel role for CD38</article-title>. <source/>Biochem Biophys Res Commun. (<year>2006</year>) <volume>345</volume>:<fpage>1386</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2006.05.042</pub-id><pub-id pub-id-type="pmid">16730329</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>AP</given-names></name><name><surname>Price</surname><given-names>NL</given-names></name><name><surname>Ling</surname><given-names>AJ</given-names></name><name><surname>Moslehi</surname><given-names>JJ</given-names></name><name><surname>Montgomery</surname><given-names>MK</given-names></name><name><surname>Rajman</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Declining NAD (+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging</article-title>. <source/>Cell. (<year>2013</year>) <volume>155</volume>:<fpage>1624</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.11.037</pub-id><pub-id pub-id-type="pmid">24360282</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camacho-Pereira</surname><given-names>J</given-names></name><name><surname>Tarrago</surname><given-names>MG</given-names></name><name><surname>Chini</surname><given-names>CCS</given-names></name><name><surname>Nin</surname><given-names>V</given-names></name><name><surname>Escande</surname><given-names>C</given-names></name><name><surname>Warner</surname><given-names>GM</given-names></name><etal></etal></person-group>. <article-title>CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism</article-title>. <source/>Cell Metab. (<year>2016</year>) <volume>23</volume>:<fpage>1127</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2016.05.006</pub-id><pub-id pub-id-type="pmid">27304511</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>MB</given-names></name><name><surname>Sinclair</surname><given-names>DA</given-names></name></person-group>. <article-title>Why NAD (+) declines during aging: it's destroyed</article-title>. <source/>Cell Metab. (<year>2016</year>) <volume>23</volume>:<fpage>965</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2016.05.022</pub-id><pub-id pub-id-type="pmid">27304496</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chini</surname><given-names>EN</given-names></name></person-group>. <article-title>CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions</article-title>. <source/>Curr Pharm Des. (<year>2009</year>) <volume>15</volume>:<fpage>57</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="pmid">19149603</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escande</surname><given-names>C</given-names></name><name><surname>Nin</surname><given-names>V</given-names></name><name><surname>Price</surname><given-names>NL</given-names></name><name><surname>Capellini</surname><given-names>V</given-names></name><name><surname>Gomes</surname><given-names>AP</given-names></name><name><surname>Barbosa</surname><given-names>MT</given-names></name><etal></etal></person-group>. <article-title>Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome</article-title>. <source/>Diabetes. (<year>2013</year>) <volume>62</volume>:<fpage>1084</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.2337/db12-1139</pub-id><pub-id pub-id-type="pmid">23172919</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>S</given-names></name><name><surname>Guarente</surname><given-names>L</given-names></name></person-group>. <article-title>NAD+ and sirtuins in aging and disease</article-title>. <source/>Trends Cell Biol. (<year>2014</year>) <volume>24</volume>:<fpage>464</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcb.2014.04.002</pub-id><pub-id pub-id-type="pmid">24786309</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdin</surname><given-names>E</given-names></name></person-group>. <article-title>NAD (+) in aging, metabolism, and neurodegeneration</article-title>. <source/>Science. (<year>2015</year>) <volume>350</volume>:<fpage>1208</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1126/science.aac4854</pub-id><pub-id pub-id-type="pmid">26785480</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higashida</surname><given-names>H</given-names></name><name><surname>Lopatina</surname><given-names>O</given-names></name><name><surname>Yoshihara</surname><given-names>T</given-names></name><name><surname>Pichugina</surname><given-names>YA</given-names></name><name><surname>Soumarokov</surname><given-names>AA</given-names></name><name><surname>Munesue</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Oxytocin signal and social behaviour: comparison among adult and infant oxytocin, oxytocin receptor and CD38 gene knockout mice</article-title>. <source/>J Neuroendocrinol. (<year>2010</year>) <volume>22</volume>:<fpage>373</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2826.2010.01976.x</pub-id><pub-id pub-id-type="pmid">20141571</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopatina</surname><given-names>O</given-names></name><name><surname>Liu</surname><given-names>HX</given-names></name><name><surname>Amina</surname><given-names>S</given-names></name><name><surname>Hashii</surname><given-names>M</given-names></name><name><surname>Higashida</surname><given-names>H</given-names></name></person-group>. <article-title>Oxytocin-induced elevation of ADP-ribosyl cyclase activity, cyclic ADP-ribose or Ca (2+) concentrations is involved in autoregulation of oxytocin secretion in the hypothalamus and posterior pituitary in male mice</article-title>. <source/>Neuropharmacology. (<year>2010</year>) <volume>58</volume>:<fpage>50</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2009.06.012</pub-id><pub-id pub-id-type="pmid">19540855</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higashida</surname><given-names>H</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name><name><surname>Munesue</surname><given-names>T</given-names></name><name><surname>Kikuchi</surname><given-names>M</given-names></name><name><surname>Minabe</surname><given-names>Y</given-names></name><name><surname>Lopatina</surname><given-names>O</given-names></name></person-group>. <article-title>CD38 gene knockout juvenile mice: a model of oxytocin signal defects in autism</article-title>. <source/>Biol Pharm Bull. (<year>2011</year>). <volume>34</volume>:<fpage>1369</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="pmid">21881219</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higashida</surname><given-names>H</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>JJ</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>WJ</given-names></name><name><surname>Akther</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Social memory, amnesia, and autism: brain oxytocin secretion is regulated by NAD+ metabolites and single nucleotide polymorphisms of CD38</article-title>. <source/>Neurochem Int. (<year>2012</year>) <volume>61</volume>:<fpage>828</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2012.01.030</pub-id><pub-id pub-id-type="pmid">22366648</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopatina</surname><given-names>O</given-names></name><name><surname>Inzhutova</surname><given-names>A</given-names></name><name><surname>Salmina</surname><given-names>AB</given-names></name><name><surname>Higashida</surname><given-names>H</given-names></name></person-group>
<article-title>The roles of oxytocin and CD38 in social or parental behaviors</article-title>. <source/>Front Neurosci. (<year>2012</year>) <volume>6</volume>:<fpage>182</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2012.00182</pub-id><pub-id pub-id-type="pmid">23335873</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musso</surname><given-names>T</given-names></name><name><surname>Deaglio</surname><given-names>S</given-names></name><name><surname>Franco</surname><given-names>L</given-names></name><name><surname>Calosso</surname><given-names>L</given-names></name><name><surname>Badolato</surname><given-names>R</given-names></name><name><surname>Garbarino</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines</article-title>. <source/>J Leukoc Biol. (<year>2001</year>) <volume>69</volume>:<fpage>605</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="pmid">11310847</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>BN</given-names></name><name><surname>Tirumurugaan</surname><given-names>KG</given-names></name><name><surname>Deshpande</surname><given-names>DA</given-names></name><name><surname>Amrani</surname><given-names>Y</given-names></name><name><surname>Panettieri</surname><given-names>RA</given-names></name><name><surname>Walseth</surname><given-names>TF</given-names></name><etal></etal></person-group>. <article-title>Transcriptional regulation of CD38 expression by tumor necrosis factor-alpha in human airway smooth muscle cells: role of NF-kappaB and sensitivity to glucocorticoids</article-title>. <source/>Faseb J. (<year>2006</year>) <volume>20</volume>:<fpage>1000</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1096/fj.05-4585fje</pub-id><pub-id pub-id-type="pmid">16571778</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matalonga</surname><given-names>J</given-names></name><name><surname>Glaria</surname><given-names>E</given-names></name><name><surname>Bresque</surname><given-names>M</given-names></name><name><surname>Escande</surname><given-names>C</given-names></name><name><surname>Carbo</surname><given-names>JM</given-names></name><name><surname>Kiefer</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>The nuclear receptor LXR limits bacterial infection of host macrophages through a mechanism that impacts cellular NAD Metabolism</article-title>. <source/>Cell Rep. (<year>2017</year>) <volume>18</volume>:<fpage>1241</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2017.01.007</pub-id><pub-id pub-id-type="pmid">28147278</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>YJ</given-names></name><name><surname>Lam</surname><given-names>CM</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name></person-group>. <article-title>The membrane-bound enzyme CD38 exists in two opposing orientations</article-title>. <source/>Sci Signal. (<year>2012</year>) <volume>5</volume>:<fpage>ra67</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.2002700</pub-id><pub-id pub-id-type="pmid">22969159</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrimp</surname><given-names>JH</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>BS</given-names></name><name><surname>MacDonald</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Revealing CD38 cellular localization using a cell permeable, mechanism-based fluorescent small-molecule probe</article-title>. <source/>J Am Chem Soc. (<year>2014</year>) <volume>136</volume>:<fpage>5656</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1021/ja411046j</pub-id><pub-id pub-id-type="pmid">24660829</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>YJ</given-names></name><name><surname>Li</surname><given-names>WH</given-names></name><name><surname>Hou</surname><given-names>YN</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>ZY</given-names></name><etal></etal></person-group>
<article-title>Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2017</year>) <volume>114</volume>, <fpage>8283</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1703718114</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malavasi</surname><given-names>F</given-names></name><name><surname>Deaglio</surname><given-names>S</given-names></name><name><surname>Funaro</surname><given-names>A</given-names></name><name><surname>Ferrero</surname><given-names>E</given-names></name><name><surname>Horenstein</surname><given-names>AL</given-names></name><name><surname>Ortolan</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology</article-title>. <source/>Physiol Rev. (<year>2008</year>) <volume>88</volume>:<fpage>841</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00035.2007</pub-id><pub-id pub-id-type="pmid">18626062</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Graeff</surname><given-names>R</given-names></name><name><surname>Kriksunov</surname><given-names>IA</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Oppenheimer</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Structural basis for enzymatic evolution from a dedicated ADP-ribosyl cyclase to a multifunctional NAD hydrolase</article-title>. <source/>J Biol Chem. (<year>2009</year>) <volume>284</volume>:<fpage>27637</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.031005</pub-id><pub-id pub-id-type="pmid">19640846</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>WK</given-names></name><name><surname>Bolton</surname><given-names>EL</given-names></name><name><surname>Cortopassi</surname><given-names>WA</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>O'Brien</surname><given-names>F</given-names></name><name><surname>Maciejewska</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Synthesis of the Ca (2+)-mobilizing messengers NAADP and cADPR by intracellular CD38 enzyme in the mouse heart: Role in beta-adrenoceptor signaling</article-title>. <source/>J Biol Chem. (<year>2017</year>) <volume>292</volume>:<fpage>13243</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M117.789347</pub-id><pub-id pub-id-type="pmid">28539361</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Essuman</surname><given-names>K</given-names></name><name><surname>Summers</surname><given-names>DW</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>DiAntonio</surname><given-names>A</given-names></name><name><surname>Milbrandt</surname><given-names>J</given-names></name></person-group>. <article-title>The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD (+) Cleavage Activity that Promotes Pathological Axonal Degeneration</article-title>. <source/>Neuron. (<year>2017</year>) <volume>93</volume>:<fpage>1334</fpage>–<lpage>1343</lpage>.e1335. <pub-id pub-id-type="doi">10.1016/j.neuron.2017.02.022</pub-id><pub-id pub-id-type="pmid">28334607</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>AK</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Leung</surname><given-names>FP</given-names></name><name><surname>Lam</surname><given-names>CM</given-names></name><name><surname>Ting</surname><given-names>KY</given-names></name><etal></etal></person-group>. <article-title>Catalysis-based inhibitors of the calcium signaling function of CD38</article-title>. <source/>Biochemistry. (<year>2012</year>) <volume>51</volume>:<fpage>555</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1021/bi201509f</pub-id><pub-id pub-id-type="pmid">22142305</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gul</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>DR</given-names></name><name><surname>Shawl</surname><given-names>AI</given-names></name><name><surname>Im</surname><given-names>SY</given-names></name><name><surname>Nam</surname><given-names>TS</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><etal></etal></person-group>. <article-title>Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) and Cyclic ADP-Ribose (cADPR) Mediate Ca2+ signaling in cardiac hypertrophy induced by beta-adrenergic stimulation</article-title>. <source/>PLoS ONE. (<year>2016</year>) <volume>11</volume>:<fpage>e0149125</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0149125</pub-id><pub-id pub-id-type="pmid">26959359</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horenstein</surname><given-names>AL</given-names></name><name><surname>Chillemi</surname><given-names>A</given-names></name><name><surname>Zaccarello</surname><given-names>G</given-names></name><name><surname>Bruzzone</surname><given-names>S</given-names></name><name><surname>Quarona</surname><given-names>V</given-names></name><name><surname>Zito</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes</article-title>. <source/>Oncoimmunology. (<year>2013</year>) <volume>2</volume>:<fpage>e26246</fpage>. <pub-id pub-id-type="doi">10.4161/onci.26246</pub-id><pub-id pub-id-type="pmid">24319640</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horenstein</surname><given-names>AL</given-names></name><name><surname>Quarona</surname><given-names>V</given-names></name><name><surname>Toscani</surname><given-names>D</given-names></name><name><surname>Costa</surname><given-names>F</given-names></name><name><surname>Chillemi</surname><given-names>A</given-names></name><name><surname>Pistoia</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma</article-title>. <source/>Mol Med. (<year>2016</year>) <volume>22</volume>:<fpage>694</fpage>–<lpage>704</lpage>. <pub-id pub-id-type="doi">10.2119/molmed.2016.00198</pub-id><pub-id pub-id-type="pmid">27761584</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Yoshimura</surname><given-names>K</given-names></name><name><surname>Kurabe</surname><given-names>N</given-names></name><name><surname>Kahyo</surname><given-names>T</given-names></name><name><surname>Kawase</surname><given-names>A</given-names></name><name><surname>Tanahashi</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer</article-title>. <source/>Oncotarget. (<year>2017</year>) <volume>8</volume>:<fpage>8738</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.14434</pub-id><pub-id pub-id-type="pmid">28060732</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shallis</surname><given-names>RM</given-names></name><name><surname>Terry</surname><given-names>CM</given-names></name><name><surname>Lim</surname><given-names>SH</given-names></name></person-group>. <article-title>The multi-faceted potential of CD38 antibody targeting in multiple myeloma</article-title>. <source/>Cancer Immunol Immunother. (<year>2017</year>) <volume>66</volume>:<fpage>697</fpage>–<lpage>703</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-017-1990-2</pub-id><pub-id pub-id-type="pmid">28341874</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assi</surname><given-names>R</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Ravandi</surname><given-names>F</given-names></name><name><surname>Daver</surname><given-names>N</given-names></name></person-group>. <article-title>Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors</article-title>. <source/>Curr Opin Hematol. (<year>2018</year>) <volume>25</volume>:<fpage>136</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1097/moh.0000000000000401</pub-id><pub-id pub-id-type="pmid">29206680</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarhus</surname><given-names>R</given-names></name><name><surname>Graeff</surname><given-names>RM</given-names></name><name><surname>Dickey</surname><given-names>DM</given-names></name><name><surname>Walseth</surname><given-names>TF</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name></person-group>. <article-title>ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP</article-title>. <source/>J Biol Chem. (<year>1995</year>) <volume>270</volume>:<fpage>30327</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="pmid">8530456</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chini</surname><given-names>EN</given-names></name><name><surname>Beers</surname><given-names>KW</given-names></name><name><surname>Dousa</surname><given-names>TP</given-names></name></person-group>. <article-title>Nicotinate adenine dinucleotide phosphate (NAADP) triggers a specific calcium release system in sea urchin eggs</article-title>. <source/>J Biol Chem. (<year>1995</year>) <volume>270</volume>:<fpage>3216</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="pmid">7852407</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chini</surname><given-names>EN</given-names></name><name><surname>Dousa</surname><given-names>TP</given-names></name></person-group>. <article-title>Enzymatic synthesis and degradation of nicotinate adenine dinucleotide phosphate (NAADP), a Ca (2+)-releasing agonist, in rat tissues</article-title>. <source/>Biochem Biophys Res Commun. (<year>1995</year>) <volume>209</volume>:<fpage>167</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.1995.1485</pub-id><pub-id pub-id-type="pmid">7726831</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soares</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>T</given-names></name><name><surname>Isbell</surname><given-names>A</given-names></name><name><surname>Yamasaki</surname><given-names>M</given-names></name><name><surname>Prakash</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>NAADP as a second messenger: neither CD38 nor base-exchange reaction are necessary for <italic>in vivo</italic> generation of NAADP in myometrial cells</article-title>. <source/>Am J Physiol Cell Physiol. (<year>2007</year>) <volume>292</volume>:<fpage>C227</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00638.2005</pub-id><pub-id pub-id-type="pmid">16790499</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Tarrago</surname><given-names>MG</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name><etal></etal></person-group>. <article-title>A high dose of isoniazid disturbs endobiotic homeostasis in mouse liver</article-title>. <source/>Drug Metab Dispos. (<year>2016</year>) <volume>44</volume>:<fpage>1742</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.116.070920</pub-id><pub-id pub-id-type="pmid">27531952</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deaglio</surname><given-names>S</given-names></name><name><surname>Aydin</surname><given-names>S</given-names></name><name><surname>Grand</surname><given-names>MM</given-names></name><name><surname>Vaisitti</surname><given-names>T</given-names></name><name><surname>Bergui</surname><given-names>L</given-names></name><name><surname>D'Arena</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells</article-title>. <source/>Mol Med. (<year>2010</year>) <volume>16</volume>:<fpage>87</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.2119/molmed.2009.00146</pub-id><pub-id pub-id-type="pmid">19956559</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cynamon</surname><given-names>MH</given-names></name><name><surname>Sorg</surname><given-names>TB</given-names></name><name><surname>Patapow</surname><given-names>A</given-names></name></person-group>. <article-title>Utilization and metabolism of NAD by Haemophilus parainfluenzae</article-title>. <source/>J Gen Microbiol. (<year>1988</year>) <volume>134</volume>:<fpage>2789</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1099/00221287-134-10-2789</pub-id><pub-id pub-id-type="pmid">3254936</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbert</surname><given-names>M</given-names></name><name><surname>Sauer</surname><given-names>E</given-names></name><name><surname>Smethurst</surname><given-names>G</given-names></name><name><surname>Kraiss</surname><given-names>A</given-names></name><name><surname>Hilpert</surname><given-names>AK</given-names></name><name><surname>Reidl</surname><given-names>J</given-names></name></person-group>. <article-title>Nicotinamide ribosyl uptake mutants in Haemophilus influenzae</article-title>. <source/>Infect Immun. (<year>2003</year>) <volume>71</volume>:<fpage>5398</fpage>–<lpage>401</lpage>. <pub-id pub-id-type="pmid">12933892</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jablonski</surname><given-names>KA</given-names></name><name><surname>Amici</surname><given-names>SA</given-names></name><name><surname>Webb</surname><given-names>LM</given-names></name><name><surname>Ruiz-Rosado</surname><given-names>Jde D</given-names></name><name><surname>Popovich</surname><given-names>PG</given-names></name><name><surname>Partida-Sanchez</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Novel markers to delineate murine M1 and M2 macrophages</article-title>. <source/>PLoS ONE. (<year>2015</year>) <volume>10</volume>:<fpage>e0145342</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0145342</pub-id><pub-id pub-id-type="pmid">26699615</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>B</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Gui</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Xue</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Blockade of CD38 diminishes lipopolysaccharide-induced macrophage classical activation and acute kidney injury involving NF-kappaB signaling suppression</article-title>. <source/>Cell Signal. (<year>2018</year>) <volume>42</volume>:<fpage>249</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2017.10.014</pub-id><pub-id pub-id-type="pmid">29080804</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Partida-Sanchez</surname><given-names>S</given-names></name><name><surname>Cockayne</surname><given-names>DA</given-names></name><name><surname>Monard</surname><given-names>S</given-names></name><name><surname>Jacobson</surname><given-names>EL</given-names></name><name><surname>Oppenheimer</surname><given-names>N</given-names></name><name><surname>Garvy</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance <italic>in vivo</italic></article-title>. <source/>Nat Med. (<year>2001</year>) <volume>7</volume>:<fpage>1209</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1038/nm1101-1209</pub-id><pub-id pub-id-type="pmid">11689885</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname><given-names>J</given-names></name><name><surname>Themeli</surname><given-names>M</given-names></name><name><surname>de</surname><given-names>Jong-Korlaar R</given-names></name><name><surname>Ruiter</surname><given-names>RWJ</given-names></name><name><surname>Poddighe</surname><given-names>PJ</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia</article-title>. <source/>Haematologica. (<year>2019</year>) <volume>104</volume>:<fpage>e100</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.3324/haematol.2018.192757</pub-id><pub-id pub-id-type="pmid">30190344</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estrada-Figueroa</surname><given-names>LA</given-names></name><name><surname>Ramirez-Jimenez</surname><given-names>Y</given-names></name><name><surname>Osorio-Trujillo</surname><given-names>C</given-names></name><name><surname>Shibayama</surname><given-names>M</given-names></name><name><surname>Navarro-Garcia</surname><given-names>F</given-names></name><name><surname>Garcia-Tovar</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Absence of CD38 delays arrival of neutrophils to the liver and innate immune response development during hepatic amoebiasis by <italic>Entamoeba histolytica</italic></article-title>. <source/>Parasite Immunol. (<year>2011</year>) <volume>33</volume>:<fpage>661</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-3024.2011.01333.x</pub-id><pub-id pub-id-type="pmid">21919917</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lischke</surname><given-names>T</given-names></name><name><surname>Heesch</surname><given-names>K</given-names></name><name><surname>Schumacher</surname><given-names>V</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Haag</surname><given-names>F</given-names></name><name><surname>Koch-Nolte</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>CD38 controls the innate immune response against Listeria monocytogenes</article-title>. <source/>Infect Immun. (<year>2013</year>) <volume>81</volume>:<fpage>4091</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/iai.00340-13</pub-id><pub-id pub-id-type="pmid">23980105</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burel</surname><given-names>JG</given-names></name><name><surname>Apte</surname><given-names>SH</given-names></name><name><surname>Groves</surname><given-names>PL</given-names></name><name><surname>Klein</surname><given-names>K</given-names></name><name><surname>McCarthy</surname><given-names>JS</given-names></name><name><surname>Doolan</surname><given-names>DL</given-names></name></person-group>. <article-title>Reduced plasmodium parasite burden associates with CD38+ CD4+ T Cells Displaying Cytolytic Potential and Impaired IFN-gamma production</article-title>. <source/>PLoS Pathog. (<year>2016</year>) <volume>12</volume>:<fpage>e1005839</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1005839</pub-id><pub-id pub-id-type="pmid">27662621</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahri</surname><given-names>R</given-names></name><name><surname>Bollinger</surname><given-names>A</given-names></name><name><surname>Bollinger</surname><given-names>T</given-names></name><name><surname>Orinska</surname><given-names>Z</given-names></name><name><surname>Bulfone-Paus</surname><given-names>S</given-names></name></person-group>. <article-title>Ectonucleotidase CD38 demarcates regulatory, memory-like CD8+ T cells with IFN-gamma-mediated suppressor activities</article-title>. <source/>PLoS ONE. (<year>2012</year>) <volume>7</volume>:<fpage>e45234</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0045234</pub-id><pub-id pub-id-type="pmid">23028866</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>AK</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Pirtskhalava</surname><given-names>T</given-names></name><name><surname>Weivoda</surname><given-names>MM</given-names></name><name><surname>Hachfeld</surname><given-names>CM</given-names></name><etal></etal></person-group>. <article-title>Targeting senescent cells alleviates obesity-induced metabolic dysfunction</article-title>. <source/>Aging Cell. (<year>2019</year>) <volume>18</volume>:<fpage>e12950</fpage>. <pub-id pub-id-type="doi">10.1111/acel.12950</pub-id><pub-id pub-id-type="pmid">30907060</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van</surname><given-names>Beek AA</given-names></name><name><surname>Van</surname><given-names>den Bossche J</given-names></name><name><surname>Mastroberardino</surname><given-names>PG</given-names></name><name><surname>de</surname><given-names>Winther MPJ</given-names></name><name><surname>Leenen</surname><given-names>PJM</given-names></name></person-group>
<article-title>Metabolic Alterations in Aging Macrophages: Ingredients for Inflammaging?</article-title>
<source/>Trends Immunol. (<year>2019</year>) <volume>40</volume>:<fpage>113</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2018.12.007</pub-id><pub-id pub-id-type="pmid">30626541</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chini</surname><given-names>EN</given-names></name><name><surname>Chini</surname><given-names>CC</given-names></name><name><surname>Kato</surname><given-names>I</given-names></name><name><surname>Takasawa</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name></person-group>. <article-title>CD38 is the major enzyme responsible for synthesis of nicotinic acid-adenine dinucleotide phosphate in mammalian tissues</article-title>. <source/>Biochem J. (<year>2002</year>) <volume>362</volume> (<issue>Pt 1</issue>):<fpage>125</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="pmid">11829748</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouchiroud</surname><given-names>L</given-names></name><name><surname>Houtkooper</surname><given-names>RH</given-names></name><name><surname>Moullan</surname><given-names>N</given-names></name><name><surname>Katsyuba</surname><given-names>E</given-names></name><name><surname>Ryu</surname><given-names>D</given-names></name><name><surname>Canto</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>The NAD (+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling</article-title>. <source/>Cell. (<year>2013</year>) <volume>154</volume>:<fpage>430</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.06.016</pub-id><pub-id pub-id-type="pmid">23870130</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar-Arnal</surname><given-names>L</given-names></name><name><surname>Katada</surname><given-names>S</given-names></name><name><surname>Orozco-Solis</surname><given-names>R</given-names></name><name><surname>Sassone-Corsi</surname><given-names>P</given-names></name></person-group>. <article-title>NAD (+)-SIRT1 control of H3K4 trimethylation through circadian deacetylation of MLL1</article-title>. <source/>Nat Struct Mol Biol. (<year>2015</year>) <volume>22</volume>:<fpage>312</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb.2990</pub-id><pub-id pub-id-type="pmid">25751424</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghuramulu</surname><given-names>N</given-names></name><name><surname>Srikantia</surname><given-names>SG</given-names></name><name><surname>Rao</surname><given-names>BS</given-names></name><name><surname>Gopalan</surname><given-names>C</given-names></name></person-group>. <article-title>Nicotinamide nucleotides in the erythrocytes of patients suffering from pellagra</article-title>. <source/>Biochem J. (<year>1965</year>) <volume>96</volume>:<fpage>837</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="pmid">4285896</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>AC</given-names></name><name><surname>Hill</surname><given-names>LJ</given-names></name><name><surname>Ramsden</surname><given-names>DB</given-names></name></person-group>. <article-title>Nicotinamide, NAD (P) (H), and Methyl-Group homeostasis evolved and became a determinant of ageing diseases: hypotheses and lessons from pellagra</article-title>. <source/>Curr Gerontol Geriatr Res. (<year>2012</year>) <volume>2012</volume>:<fpage>302875</fpage>. <pub-id pub-id-type="doi">10.1155/2012/302875</pub-id><pub-id pub-id-type="pmid">22536229</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>North</surname><given-names>BJ</given-names></name><name><surname>Rosenberg</surname><given-names>MA</given-names></name><name><surname>Jeganathan</surname><given-names>KB</given-names></name><name><surname>Hafner</surname><given-names>AV</given-names></name><name><surname>Michan</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>SIRT2 induces the checkpoint kinase BubR1 to increase lifespan</article-title>. <source/>Embo J. (<year>2014</year>) <volume>33</volume>:<fpage>1438</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.15252/embj.201386907</pub-id><pub-id pub-id-type="pmid">24825348</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>KF</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name><name><surname>Stein</surname><given-names>LR</given-names></name><name><surname>Grozio</surname><given-names>A</given-names></name><name><surname>Kubota</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice</article-title>. <source/>Cell Metab. (<year>2016</year>) <volume>24</volume>:<fpage>795</fpage>–<lpage>806</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2016.09.013</pub-id><pub-id pub-id-type="pmid">28068222</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chini</surname><given-names>CCS</given-names></name><name><surname>Tarrago</surname><given-names>MG</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group>. <article-title>NAD and the aging process: Role in life, death and everything in between</article-title>. <source/>Mol Cell Endocrinol. (<year>2017</year>) <volume>455</volume>:<fpage>62</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2016.11.003</pub-id><pub-id pub-id-type="pmid">27825999</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>SR</given-names></name><name><surname>Huang</surname><given-names>XZ</given-names></name><name><surname>Xie</surname><given-names>QH</given-names></name><name><surname>Xu</surname><given-names>YY</given-names></name><name><surname>Shang</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Nicotinamide Mononucleotide, an NAD (+) Precursor, Rescues Age-Associated Susceptibility to AKI in a Sirtuin 1-Dependent Manner</article-title>. <source/>J Am Soc Nephrol. (<year>2017</year>) <volume>28</volume>:<fpage>2337</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1681/asn.2016040385</pub-id><pub-id pub-id-type="pmid">28246130</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Enriquez</surname><given-names>A</given-names></name><name><surname>Rapadas</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Moreau</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>NAD Deficiency, Congenital Malformations, and Niacin Supplementation</article-title>. <source/>N Engl J Med. (<year>2017</year>) <volume>377</volume>:<fpage>544</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1616361</pub-id><pub-id pub-id-type="pmid">28792876</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>MK</given-names></name><name><surname>Jacobson</surname><given-names>EL</given-names></name></person-group>. <article-title>Vitamin B3 in health and disease: toward the second century of discovery</article-title>. <source/>Methods Mol Biol. (<year>2018</year>) <volume>1813</volume>:<fpage>3</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-8588-3_1</pub-id><pub-id pub-id-type="pmid">30097857</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheibye-Knudsen</surname><given-names>M</given-names></name><name><surname>Mitchell</surname><given-names>SJ</given-names></name><name><surname>Fang</surname><given-names>EF</given-names></name><name><surname>Iyama</surname><given-names>T</given-names></name><name><surname>Ward</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>A high-fat diet and NAD (+) activate Sirt1 to rescue premature aging in cockayne syndrome</article-title>. <source/>Cell Metab. (<year>2014</year>) <volume>20</volume>:<fpage>840</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2014.10.005</pub-id><pub-id pub-id-type="pmid">25440059</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garten</surname><given-names>A</given-names></name><name><surname>Schuster</surname><given-names>S</given-names></name><name><surname>Penke</surname><given-names>M</given-names></name><name><surname>Gorski</surname><given-names>T</given-names></name><name><surname>de</surname><given-names>Giorgis T</given-names></name><name><surname>Kiess</surname><given-names>W</given-names></name></person-group>. <article-title>Physiological and pathophysiological roles of NAMPT and NAD metabolism</article-title>. <source/>Nat Rev Endocrinol. (<year>2015</year>) <volume>11</volume>:<fpage>535</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1038/nrendo.2015.117</pub-id><pub-id pub-id-type="pmid">26215259</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>SI</given-names></name></person-group>. <article-title>The NAD World 2</article-title>.0: the importance of the inter-tissue communication mediated by NAMPT/NAD (+)/SIRT1 in mammalian aging and longevity control. <source/>NPJ Syst Biol Appl. (<year>2016</year>) <volume>2</volume>:<fpage>16018</fpage>. <pub-id pub-id-type="doi">10.1038/npjsba.2016.18</pub-id><pub-id pub-id-type="pmid">28725474</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chini</surname><given-names>C</given-names></name><name><surname>Hogan</surname><given-names>KA</given-names></name><name><surname>Warner</surname><given-names>GM</given-names></name><name><surname>Tarrago</surname><given-names>MG</given-names></name><name><surname>Peclat</surname><given-names>TR</given-names></name><name><surname>Tchkonia</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>The NADase CD38 is induced by factors secreted from senescent cells providing a potential link between senescence and age-related cellular NAD (+) decline</article-title>. <source/>Biochem Biophys Res Commun. (<year>2019</year>) <volume>513</volume>:<fpage>486</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2019.03.199</pub-id><pub-id pub-id-type="pmid">30975470</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bu</surname><given-names>X</given-names></name><name><surname>Kato</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>JA</given-names></name><name><surname>Merino</surname><given-names>MJ</given-names></name><name><surname>Schrump</surname><given-names>DS</given-names></name><name><surname>Lund</surname><given-names>FE</given-names></name><etal></etal></person-group>. <article-title>CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells</article-title>. <source/>Carcinogenesis. (<year>2018</year>) <volume>39</volume>:<fpage>242</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgx137</pub-id><pub-id pub-id-type="pmid">29228209</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mottahedeh</surname><given-names>J</given-names></name><name><surname>Haffner</surname><given-names>MC</given-names></name><name><surname>Grogan</surname><given-names>TR</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Crowell</surname><given-names>PD</given-names></name><name><surname>Beltran</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>CD38 is methylated in prostate cancer and regulates extracellular NAD ()</article-title>. <source/>Cancer Metab. (<year>2018</year>) <volume>6</volume>:<fpage>13</fpage>. <pub-id pub-id-type="doi">10.1186/s40170-018-0186-3</pub-id><pub-id pub-id-type="pmid">30258629</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chini</surname><given-names>CC</given-names></name><name><surname>Guerrico</surname><given-names>AM</given-names></name><name><surname>Nin</surname><given-names>V</given-names></name><name><surname>Camacho-Pereira</surname><given-names>J</given-names></name><name><surname>Escande</surname><given-names>C</given-names></name><name><surname>Barbosa</surname><given-names>MT</given-names></name><etal></etal></person-group>. <article-title>Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors</article-title>. <source/>Clin Cancer Res. (<year>2014</year>) <volume>20</volume>:<fpage>120</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.ccr-13-0150</pub-id><pub-id pub-id-type="pmid">24025713</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grozio</surname><given-names>A</given-names></name><name><surname>Sociali</surname><given-names>G</given-names></name><name><surname>Sturla</surname><given-names>L</given-names></name><name><surname>Caffa</surname><given-names>I</given-names></name><name><surname>Soncini</surname><given-names>D</given-names></name><name><surname>Salis</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells</article-title>. <source/>J Biol Chem. (<year>2013</year>) <volume>288</volume>:<fpage>25938</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.470435</pub-id><pub-id pub-id-type="pmid">23880765</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deckert</surname><given-names>J</given-names></name><name><surname>Wetzel</surname><given-names>MC</given-names></name><name><surname>Bartle</surname><given-names>LM</given-names></name><name><surname>Skaletskaya</surname><given-names>A</given-names></name><name><surname>Goldmacher</surname><given-names>VS</given-names></name><name><surname>Vallee</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies</article-title>. <source/>Clin Cancer Res. (<year>2014</year>) <volume>20</volume>:<fpage>4574</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.ccr-14-0695</pub-id><pub-id pub-id-type="pmid">24987056</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blacher</surname><given-names>E</given-names></name><name><surname>Ben</surname><given-names>Baruch B</given-names></name><name><surname>Levy</surname><given-names>A</given-names></name><name><surname>Geva</surname><given-names>N</given-names></name><name><surname>Green</surname><given-names>KD</given-names></name><name><surname>Garneau-Tsodikova</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Inhibition of glioma progression by a newly discovered CD38 inhibitor</article-title>. <source/>Int J Cancer. (<year>2015</year>) <volume>136</volume>:<fpage>1422</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.29095</pub-id><pub-id pub-id-type="pmid">25053177</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horenstein</surname><given-names>AL</given-names></name><name><surname>Chillemi</surname><given-names>A</given-names></name><name><surname>Quarona</surname><given-names>V</given-names></name><name><surname>Zito</surname><given-names>A</given-names></name><name><surname>Roato</surname><given-names>I</given-names></name><name><surname>Morandi</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>NAD (+)-metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model</article-title>. <source/>Cells. (<year>2015</year>) <volume>4</volume>:<fpage>520</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.3390/cells4030520</pub-id><pub-id pub-id-type="pmid">26393653</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Acharya</surname><given-names>C</given-names></name><name><surname>An</surname><given-names>G</given-names></name><name><surname>Wen</surname><given-names>K</given-names></name><name><surname>Qiu</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma</article-title>. <source/>Clin Cancer Res. (<year>2017</year>) <volume>23</volume>:<fpage>4290</fpage>–<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.ccr-16-3192</pub-id><pub-id pub-id-type="pmid">28249894</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krejcik</surname><given-names>J</given-names></name><name><surname>Frerichs</surname><given-names>KA</given-names></name><name><surname>Nijhof</surname><given-names>IS</given-names></name><name><surname>van</surname><given-names>Kessel B</given-names></name><name><surname>van</surname><given-names>Velzen JF</given-names></name><name><surname>Bloem</surname><given-names>AC</given-names></name><etal></etal></person-group>. <article-title>Monocytes and Granulocytes Reduce CD38 expression levels on myeloma cells in patients treated with daratumumab</article-title>. <source/>Clin Cancer Res. (<year>2017</year>) <volume>23</volume>:<fpage>7498</fpage>–<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.ccr-17-2027</pub-id><pub-id pub-id-type="pmid">29025767</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>S</given-names></name><name><surname>Daenthanasanmak</surname><given-names>A</given-names></name><name><surname>Chakraborty</surname><given-names>P</given-names></name><name><surname>Wyatt</surname><given-names>MW</given-names></name><name><surname>Dhar</surname><given-names>P</given-names></name><name><surname>Selvam</surname><given-names>SP</given-names></name><etal></etal></person-group>. <article-title>CD38-NAD (+)Axis regulates immunotherapeutic anti-tumor T cell response</article-title>. <source/>Cell Metab. (<year>2018</year>) <volume>27</volume>:<fpage>85</fpage>–<lpage>100</lpage>.e108. <pub-id pub-id-type="doi">10.1016/j.cmet.2017.10.006</pub-id><pub-id pub-id-type="pmid">29129787</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van</surname><given-names>de Donk N</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Malavasi</surname><given-names>F</given-names></name></person-group>
<article-title>CD38 antibodies in multiple myeloma: back to the future</article-title>. <source/>Blood. (<year>2018</year>) <volume>131</volume>:<fpage>13</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2017-06-740944</pub-id><pub-id pub-id-type="pmid">29118010</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayakawa</surname><given-names>K</given-names></name><name><surname>Esposito</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Terasaki</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Transfer of mitochondria from astrocytes to neurons after stroke</article-title>. <source/>Nature. (<year>2016</year>) <volume>535</volume>:<fpage>551</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/nature18928</pub-id><pub-id pub-id-type="pmid">27466127</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marlein</surname><given-names>CR</given-names></name><name><surname>Piddock</surname><given-names>RE</given-names></name><name><surname>Mistry</surname><given-names>JJ</given-names></name><name><surname>Zaitseva</surname><given-names>L</given-names></name><name><surname>Hellmich</surname><given-names>C</given-names></name><name><surname>Horton</surname><given-names>RH</given-names></name><etal></etal></person-group>. <article-title>CD38-driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma</article-title>. <source/>Cancer Res. (<year>2019</year>) <volume>79</volume>:<fpage>2285</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.can-18-0773</pub-id><pub-id pub-id-type="pmid">30622116</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rustom</surname><given-names>A</given-names></name><name><surname>Saffrich</surname><given-names>R</given-names></name><name><surname>Markovic</surname><given-names>I</given-names></name><name><surname>Walther</surname><given-names>P</given-names></name><name><surname>Gerdes</surname><given-names>HH</given-names></name></person-group>. <article-title>Nanotubular highways for intercellular organelle transport</article-title>. <source/>Science. (<year>2004</year>) <volume>303</volume>:<fpage>1007</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1126/science.1093133</pub-id><pub-id pub-id-type="pmid">14963329</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spees</surname><given-names>JL</given-names></name><name><surname>Olson</surname><given-names>SD</given-names></name><name><surname>Whitney</surname><given-names>MJ</given-names></name><name><surname>Prockop</surname><given-names>DJ</given-names></name></person-group>. <article-title>Mitochondrial transfer between cells can rescue aerobic respiration</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2006</year>) <volume>103</volume>:<fpage>1283</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0510511103</pub-id><pub-id pub-id-type="pmid">16432190</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquier</surname><given-names>J</given-names></name><name><surname>Guerrouahen</surname><given-names>BS</given-names></name><name><surname>Al</surname><given-names>Thawadi H</given-names></name><name><surname>Ghiabi</surname><given-names>P</given-names></name><name><surname>Maleki</surname><given-names>M</given-names></name><name><surname>Abu-Kaoud</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance</article-title>. <source/>J Transl Med. (<year>2013</year>) <volume>11</volume>:<fpage>94</fpage>. <pub-id pub-id-type="doi">10.1186/1479-5876-11-94</pub-id><pub-id pub-id-type="pmid">23574623</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>AS</given-names></name><name><surname>Baty</surname><given-names>JW</given-names></name><name><surname>Dong</surname><given-names>LF</given-names></name><name><surname>Bezawork-Geleta</surname><given-names>A</given-names></name><name><surname>Endaya</surname><given-names>B</given-names></name><name><surname>Goodwin</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA</article-title>. <source/>Cell Metab. (<year>2015</year>) <volume>21</volume>:<fpage>81</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2014.12.003</pub-id><pub-id pub-id-type="pmid">25565207</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>LF</given-names></name><name><surname>Kovarova</surname><given-names>J</given-names></name><name><surname>Bajzikova</surname><given-names>M</given-names></name><name><surname>Bezawork-Geleta</surname><given-names>A</given-names></name><name><surname>Svec</surname><given-names>D</given-names></name><name><surname>Endaya</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Horizontal transfer of whole mitochondria restores tumorigenic potential in mitochondrial DNA-deficient cancer cells</article-title>. <source/>Elife. (<year>2017</year>) <volume>6</volume>:<fpage>e22187</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.22187</pub-id><pub-id pub-id-type="pmid">28195532</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Tunneling nanotubes promote intercellular mitochondria transfer followed by increased invasiveness in bladder cancer cells</article-title>. <source/>Oncotarget. (<year>2017</year>) <volume>8</volume>:<fpage>15539</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.14695</pub-id><pub-id pub-id-type="pmid">28107184</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>MD</given-names></name><name><surname>O'Sullivan</surname><given-names>D</given-names></name><name><surname>Pearce</surname><given-names>EL</given-names></name></person-group>. <article-title>T cell metabolism drives immunity</article-title>. <source/>J Exp Med. (<year>2015</year>) <volume>212</volume>:<fpage>1345</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20151159</pub-id><pub-id pub-id-type="pmid">26261266</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Fang</surname><given-names>JY</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group>. <article-title>Regulation of PD-L1: emerging routes for targeting tumor immune evasion</article-title>. <source/>Front Pharmacol. (<year>2018</year>) <volume>9</volume>:<fpage>536</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2018.00536</pub-id><pub-id pub-id-type="pmid">29910728</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Diao</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yi</surname><given-names>X</given-names></name><name><surname>Rodriguez</surname><given-names>BL</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade</article-title>. <source/>Cancer Discov. (<year>2018</year>) <volume>8</volume>:<fpage>1156</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.cd-17-1033</pub-id><pub-id pub-id-type="pmid">30012853</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>M</given-names></name><name><surname>Jiao</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors</article-title>. <source/>Mol Cancer. (<year>2018</year>) <volume>17</volume>:<fpage>129</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-018-0864-3</pub-id><pub-id pub-id-type="pmid">30139382</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erlebacher</surname><given-names>A</given-names></name></person-group>. <article-title>Immunology of the maternal-fetal interface</article-title>. <source/>Annu Rev Immunol. (<year>2013</year>) <volume>31</volume>:<fpage>387</fpage>–<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-100003</pub-id><pub-id pub-id-type="pmid">23298207</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aluvihare</surname><given-names>VR</given-names></name><name><surname>Betz</surname><given-names>AG</given-names></name></person-group>. <article-title>The role of regulatory T cells in alloantigen tolerance</article-title>. <source/>Immunol Rev. (<year>2006</year>) <volume>212</volume>:<fpage>330</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1111/j.0105-2896.2006.00408.x</pub-id><pub-id pub-id-type="pmid">16903924</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>SA</given-names></name><name><surname>Guerin</surname><given-names>LR</given-names></name><name><surname>Moldenhauer</surname><given-names>LM</given-names></name><name><surname>Hayball</surname><given-names>JD</given-names></name></person-group>. <article-title>Activating T regulatory cells for tolerance in early pregnancy - the contribution of seminal fluid</article-title>. <source/>J Reprod Immunol. (<year>2009</year>) <volume>83</volume>:<fpage>109</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.jri.2009.08.003</pub-id><pub-id pub-id-type="pmid">19875178</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>DA</given-names></name><name><surname>Rahmati</surname><given-names>M</given-names></name><name><surname>Gohner</surname><given-names>C</given-names></name><name><surname>Bensussan</surname><given-names>A</given-names></name><name><surname>Markert</surname><given-names>UR</given-names></name><name><surname>Chaouat</surname><given-names>G</given-names></name></person-group>. <article-title>Seminal plasma peptides may determine maternal immune response that alters success or failure of pregnancy in the abortion-prone CBAxDBA/2 model</article-title>. <source/>J Reprod Immunol. (<year>2013</year>) <volume>99</volume>:<fpage>46</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.jri.2013.03.006</pub-id><pub-id pub-id-type="pmid">23701834</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zielinska</surname><given-names>W</given-names></name><name><surname>Barata</surname><given-names>H</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group>. <article-title>Metabolism of cyclic ADP-ribose: Zinc is an endogenous modulator of the cyclase/NAD glycohydrolase ratio of a CD38-like enzyme from human seminal fluid</article-title>. <source/>Life Sci. (<year>2004</year>) <volume>74</volume>:<fpage>1781</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="pmid">14741735</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>BJ</given-names></name><name><surname>Choi</surname><given-names>YM</given-names></name><name><surname>Rah</surname><given-names>SY</given-names></name><name><surname>Park</surname><given-names>DR</given-names></name><name><surname>Park</surname><given-names>SA</given-names></name><name><surname>Chung</surname><given-names>YJ</given-names></name><etal></etal></person-group>. <article-title>Seminal CD38 is a pivotal regulator for fetomaternal tolerance</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2015</year>) <volume>112</volume>:<fpage>1559</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1413493112</pub-id><pub-id pub-id-type="pmid">25591581</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de</surname><given-names>Weers M</given-names></name><name><surname>Tai</surname><given-names>YT</given-names></name><name><surname>van</surname><given-names>der Veer MS</given-names></name><name><surname>Bakker</surname><given-names>JM</given-names></name><name><surname>Vink</surname><given-names>T</given-names></name><name><surname>Jacobs</surname><given-names>DC</given-names></name><etal></etal></person-group>
<article-title>Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors</article-title>. <source/>J Immunol. (<year>2011</year>) <volume>186</volume>:<fpage>1840</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1003032</pub-id><pub-id pub-id-type="pmid">21187443</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lokhorst</surname><given-names>HM</given-names></name><name><surname>Plesner</surname><given-names>T</given-names></name><name><surname>Laubach</surname><given-names>JP</given-names></name><name><surname>Nahi</surname><given-names>H</given-names></name><name><surname>Gimsing</surname><given-names>P</given-names></name><name><surname>Hansson</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Targeting CD38 with daratumumab monotherapy in multiple myeloma</article-title>. <source/>N Engl J Med. (<year>2015</year>) <volume>373</volume>:<fpage>1207</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1506348</pub-id><pub-id pub-id-type="pmid">26308596</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nijhof</surname><given-names>IS</given-names></name><name><surname>Casneuf</surname><given-names>T</given-names></name><name><surname>van</surname><given-names>Velzen J</given-names></name><name><surname>van</surname><given-names>Kessel B</given-names></name><name><surname>Axel</surname><given-names>AE</given-names></name><name><surname>Syed</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma</article-title>. <source/>Blood. (<year>2016</year>) <volume>128</volume>:<fpage>959</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2016-03-703439</pub-id><pub-id pub-id-type="pmid">27307294</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>T</given-names></name><name><surname>Baz</surname><given-names>R</given-names></name><name><surname>Benson</surname><given-names>DM</given-names></name><name><surname>Lendvai</surname><given-names>N</given-names></name><name><surname>Wolf</surname><given-names>J</given-names></name><name><surname>Munster</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma</article-title>. <source/>Blood. (<year>2017</year>) <volume>129</volume>:<fpage>3294</fpage>–<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2016-09-740787</pub-id><pub-id pub-id-type="pmid">28483761</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manna</surname><given-names>A</given-names></name><name><surname>Aulakh</surname><given-names>S</given-names></name><name><surname>Jani</surname><given-names>P</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Akhtar</surname><given-names>S</given-names></name><name><surname>Coignet</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia (CLL)</article-title>. <source/>Clin Cancer Res. (<year>2019</year>). <pub-id pub-id-type="doi">10.1158/1078-0432.ccr-18-3412.</pub-id> [Epub ahead of print].</mixed-citation>
</ref>
<ref id="B100">
<label>100.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roepcke</surname><given-names>S</given-names></name><name><surname>Plock</surname><given-names>N</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Fedyk</surname><given-names>ER</given-names></name><name><surname>Lahu</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial</article-title>. <source/>Pharmacol Res Perspect. (<year>2018</year>) <volume>6</volume>:<fpage>e00402</fpage>. <pub-id pub-id-type="doi">10.1002/prp2.402</pub-id><pub-id pub-id-type="pmid">29864242</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slama</surname><given-names>JT</given-names></name><name><surname>Simmons</surname><given-names>AM</given-names></name></person-group>. <article-title>Carbanicotinamide adenine dinucleotide: synthesis and enzymological properties of a carbocyclic analogue of oxidized nicotinamide adenine dinucleotide</article-title>. <source/>Biochemistry. (<year>1988</year>) <volume>27</volume>:<fpage>183</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="pmid">2831953</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellenberger</surname><given-names>E</given-names></name><name><surname>Kuhn</surname><given-names>I</given-names></name><name><surname>Schuber</surname><given-names>F</given-names></name><name><surname>Muller-Steffner</surname><given-names>H</given-names></name></person-group>. <article-title>Flavonoids as inhibitors of human CD38</article-title>. <source/>Bioorg Med Chem Lett. (<year>2011</year>) <volume>21</volume>:<fpage>3939</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2011.05.022</pub-id><pub-id pub-id-type="pmid">21641214</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becherer</surname><given-names>JD</given-names></name><name><surname>Boros</surname><given-names>EE</given-names></name><name><surname>Carpenter</surname><given-names>TY</given-names></name><name><surname>Cowan</surname><given-names>DJ</given-names></name><name><surname>Deaton</surname><given-names>DN</given-names></name><name><surname>Haffner</surname><given-names>CD</given-names></name><etal></etal></person-group>. <article-title>Discovery of 4-Amino-8-quinoline carboxamides as novel, submicromolar inhibitors of NAD-Hydrolyzing Enzyme CD38</article-title>. <source/>J Med Chem. (<year>2015</year>) <volume>58</volume>:<fpage>7021</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00992</pub-id><pub-id pub-id-type="pmid">26267483</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haffner</surname><given-names>CD</given-names></name><name><surname>Becherer</surname><given-names>JD</given-names></name><name><surname>Boros</surname><given-names>EE</given-names></name><name><surname>Cadilla</surname><given-names>R</given-names></name><name><surname>Carpenter</surname><given-names>T</given-names></name><name><surname>Cowan</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Discovery, synthesis, and biological evaluation of thiazoloquin (az)olin (on)es as potent CD38 inhibitors</article-title>. <source/>J Med Chem. (<year>2015</year>) <volume>58</volume>:<fpage>3548</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1021/jm502009h</pub-id><pub-id pub-id-type="pmid">25828863</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Xue</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group>. <article-title>Comparative analysis of pharmacophore features and quantitative structure-activity relationships for CD38 covalent and non-covalent inhibitors</article-title>. <source/>Chem Biol Drug Des. (<year>2015</year>) <volume>86</volume>:<fpage>1411</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1111/cbdd.12606</pub-id><pub-id pub-id-type="pmid">26072680</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarrago</surname><given-names>MG</given-names></name><name><surname>Chini</surname><given-names>CCS</given-names></name><name><surname>Kanamori</surname><given-names>KS</given-names></name><name><surname>Warner</surname><given-names>GM</given-names></name><name><surname>Caride</surname><given-names>A</given-names></name><name><surname>de</surname><given-names>Oliveira GC</given-names></name><etal></etal></person-group>. <article-title>A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD (+) decline</article-title>. <source/>Cell Metab. (<year>2018</year>) <volume>27</volume>:<fpage>1081</fpage>–<lpage>1095</lpage>.e1010. <pub-id pub-id-type="doi">10.1016/j.cmet.2018.03.016</pub-id><pub-id pub-id-type="pmid">29719225</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boslett</surname><given-names>J</given-names></name><name><surname>Hemann</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Zweier</surname><given-names>JL</given-names></name></person-group>. <article-title>Luteolinidin protects the postischemic heart through CD38 inhibition with preservation of NAD (P) (H)</article-title>. <source/>J Pharmacol Exp Ther. (<year>2017</year>) <volume>361</volume>:<fpage>99</fpage>–<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.116.239459</pub-id><pub-id pub-id-type="pmid">28108596</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiavoni</surname><given-names>I</given-names></name><name><surname>Scagnolari</surname><given-names>C</given-names></name><name><surname>Horenstein</surname><given-names>AL</given-names></name><name><surname>Leone</surname><given-names>P</given-names></name><name><surname>Pierangeli</surname><given-names>A</given-names></name><name><surname>Malavasi</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>CD38 modulates respiratory syncytial virus-driven proinflammatory processes in human monocyte-derived dendritic cells</article-title>. <source/>Immunology. (<year>2018</year>) <volume>154</volume>:<fpage>122</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/imm.12873</pub-id><pub-id pub-id-type="pmid">29178427</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller-Steffner</surname><given-names>HM</given-names></name><name><surname>Malver</surname><given-names>O</given-names></name><name><surname>Hosie</surname><given-names>L</given-names></name><name><surname>Oppenheimer</surname><given-names>NJ</given-names></name><name><surname>Schuber</surname><given-names>F</given-names></name></person-group>. <article-title>Slow-binding inhibition of NAD+ glycohydrolase by arabino analogues of beta-NAD</article-title>. <source/>J Biol Chem. (<year>1992</year>) <volume>267</volume>:<fpage>9606</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="pmid">1315761</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauve</surname><given-names>AA</given-names></name><name><surname>Munshi</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Schramm</surname><given-names>VL</given-names></name></person-group>. <article-title>The reaction mechanism for CD38. A single intermediate is responsible for cyclization, hydrolysis, and base-exchange chemistries</article-title>. <source/>Biochemistry. (<year>1998</year>) <volume>37</volume>:<fpage>13239</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1021/bi981248s</pub-id><pub-id pub-id-type="pmid">9748331</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauve</surname><given-names>AA</given-names></name><name><surname>Schramm</surname><given-names>VL</given-names></name></person-group>. <article-title>Mechanism-based inhibitors of CD38: a mammalian cyclic ADP-ribose synthetase</article-title>. <source/>Biochemistry. (<year>2002</year>) <volume>41</volume>:<fpage>8455</fpage>−<lpage>63</lpage>. <pub-id pub-id-type="pmid">12081495</pub-id></mixed-citation>
</ref>
</ref-list>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item>
<term>NAD<sup>+</sup></term>
<def>
<p>Nicotinamide adenine dinucleotide</p>
</def>
</def-item>
<def-item>
<term>NMN</term>
<def>
<p>Nicotinamide mononucleotide</p>
</def>
</def-item>
<def-item>
<term>NR</term>
<def>
<p>Nicotinamide riboside</p>
</def>
</def-item>
<def-item>
<term>NAADP</term>
<def>
<p>Nicotinic acid adenine dinucleotide phosphate</p>
</def>
</def-item>
<def-item>
<term>ADP</term>
<def>
<p>Adenosine diphosphate</p>
</def>
</def-item>
<def-item>
<term>ADPR</term>
<def>
<p>ADP-ribose</p>
</def>
</def-item>
<def-item>
<term>cADPR</term>
<def>
<p>cyclic ADP-ribose</p>
</def>
</def-item>
<def-item>
<term>NADP<sup>+</sup></term>
<def>
<p>Nicotinamide adenine dinucleotide phosphate</p>
</def>
</def-item>
<def-item>
<term>SARM1</term>
<def>
<p>Sterile alpha and TIR Motif Containing 1</p>
</def>
</def-item>
<def-item>
<term>VACTERL, Vertebral defects, trachea-esophageal fistula, renal anomalies</term>
<def>
<p>and limb abnormalities</p>
</def>
</def-item>
<def-item>
<term>RXR</term>
<def>
<p>Retinoid X receptors</p>
</def>
</def-item>
<def-item>
<term>LXR</term>
<def>
<p>Liver X receptor</p>
</def>
</def-item>
<def-item>
<term>STAT</term>
<def>
<p>Signal transducer and activator of transcription</p>
</def>
</def-item>
<def-item>
<term>PARP</term>
<def>
<p>Poly ADP ribose polymerase</p>
</def>
</def-item>
<def-item>
<term>PD-1</term>
<def>
<p>Programmed cell death protein 1</p>
</def>
</def-item>
<def-item>
<term>PD-L1</term>
<def>
<p>Programmed death ligand 1.</p>
</def>
</def-item>
</def-list>
</glossary>
</back>
</article>
</pmc-articleset>